Novo Nordisk Foundation to support crucial education of health professionals in India and East Africa with up to DKK 1bn (USD 140m)
- Details
- Category: Novo Nordisk
The global shortage of qualified health professionals is an increasing challenge. According to the WHO, an additional 10 million health professionals will be needed by 2030. The demand is particularly acute in low- and middle-income countries, where health systems are already under immense pressure. With the launch of the Partnership for Education of Health Professionals (PEP), the Novo Nordisk Foundation takes a step towards reducing inequity in health by initially targeting the education of health professionals in underserved regions in India and East Africa.
Bayer Pharmaceuticals accelerates innovations for patients
- Details
- Category: Bayer
At its annual Pharma Media Day 2023, Bayer presented the latest progress in the ongoing transformation of its pharmaceutical business focusing on accelerating innovative healthcare solutions for the benefits of patients and delivering long-term, sustainable business growth.
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
- Details
- Category: Novartis
Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time gene therapy for the treatment of spinal muscular atrophy (SMA). Latest data from two Long-Term Follow-Up (LTFU) studies, LT-001 and LT-002, show the continued efficacy and durability of Zolgensma across a range of patient populations, with an overall benefit-risk profile that remains favorable.
CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
- Details
- Category: Business
The 20th anniversary edition of the CPHI Pharma Awards is now open for entries, with three new categories created to reflect the surge of innovation sweeping the industry - from new methodologies to sustainability and philanthropic initiatives.
In the last year, pharma has continued its rapid rate of innovation embracing the speed of pandemic R&D, but added to this are new social goals that aim to improve the wider world as well as bottom lines and therapeutic/device options.
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
- Details
- Category: Business
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-powered drug discovery company, has integrated advanced AI chat functionality based on recent advances in large language models into its PandaOmics platform. The new feature, "ChatPandaGPT," enables researchers to have natural language conversations with the platform and efficiently navigate and analyze large datasets, facilitating the discovery of potential therapeutic targets and biomarkers in a more efficient manner.
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
- Details
- Category: Bayer
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG, announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials.
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
- Details
- Category: Novartis
Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.
More Pharma News ...
- AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
- Pfizer invests $43 billion to battle cancer
- Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spray receives FDA approval
- US FDA Advisory Committee votes to support effectiveness and safety of GSK's respiratory syncytial virus older adult vaccine candidate
- Pfizer receives positive FDA Advisory Committee votes supporting potential approval for vaccine candidate to help combat RSV in older adults
- AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
- Pfizer's elranatamab receives FDA and EMA filing acceptance